

# Joon Hyeok Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8879311/publications.pdf>

Version: 2024-02-01

83  
papers

2,324  
citations

304743

22  
h-index

243625

44  
g-index

85  
all docs

85  
docs citations

85  
times ranked

3567  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	1.3	371
2	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	12.1	149
3	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	7.3	144
4	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	7.3	106
5	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.4	104
6	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	8.2	68
7	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	7.3	66
8	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	3.9	65
9	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
10	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	4.2	62
11	The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	3.9	51
12	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	3.7	50
13	Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3235-3242.	2.3	44
14	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. <i>PLoS ONE</i> , 2015, 10, e0124434.	2.5	43
15	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	8.9	42
16	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 516-528.	8.9	42
17	Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. <i>Radiotherapy and Oncology</i> , 2016, 118, 408-415.	0.6	38
18	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. <i>OncImmunology</i> , 2017, 6, e1328335.	4.6	38

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. <i>Liver Cancer</i> , 2021, 10, 52-62.	7.7	30
20	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2014, 234, 270-275.	0.8	29
21	Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2015, 209, 391-397.	1.8	27
22	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 47794-47807.	1.8	24
23	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	2.6	24
24	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1100-1106.	2.8	23
25	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	2.3	23
26	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 477-486.	8.9	23
27	Single hepatocellular carcinoma $\geq$ 3 cm in left lateral segment: Liver resection or radiofrequency ablation. <i>World Journal of Gastroenterology</i> , 2014, 20, 4059.	3.3	22
28	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	2.9	22
29	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
30	Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1159-1167.	3.7	21
31	Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2015, 33, 217.	1.5	21
32	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	1.0	20
33	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 32.	1.7	19
34	Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 1013.	4.1	18
35	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	1.7	17
36	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2028-2035.	2.8	17

#	ARTICLE	IF	CITATIONS
37	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2016, 10, 939-947.	2.9	15
38	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 3785.	3.3	15
39	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	4.2	15
40	Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors. <i>Gut and Liver</i> , 2014, 8, 543-551.	2.9	15
41	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2021, 53, 1004-1010.	0.9	14
42	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	2.9	14
43	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. <i>Gut and Liver</i> , 2016, 10, 796-802.	2.9	14
44	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3354-3362.	2.3	13
45	Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1559-1567.	1.7	13
46	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	2.0	13
47	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	8.9	13
48	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	3.3	13
49	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 283.	8.9	12
50	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	2.5	12
51	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>PLoS ONE</i> , 2019, 14, e0213547.	2.5	12
52	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. <i>Oncotarget</i> , 2017, 8, 52651-52664.	1.8	12
53	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. <i>Hepatology International</i> , 2013, 7, 1010-1018.	4.2	11
54	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 65-78.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4565-4573.	2.3	11
56	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	7.3	10
57	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	2.5	9
58	Can the model for end-stage liver disease score replace the indocyanine green clearance test in the selection of right hemihepatectomy in Child-Pugh class A?. <i>Annals of Surgical Treatment and Research</i> , 2014, 86, 122.	1.0	8
59	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 739-746.	2.0	8
60	High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients. <i>Annals of Surgical Treatment and Research</i> , 2014, 86, 256.	1.0	7
61	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 232.	8.9	7
62	Primary hepatic neuroendocrine carcinoma. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2013, 17, 34.	1.0	6
63	Enhanced Resolution of Eosinophilic Liver Abscess Associated with Toxocariasis by Albendazole Treatment. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2015, 65, 222.	0.4	6
64	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 331-338.	2.5	6
65	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	2.2	6
66	Baraclev&reg; vs Baraclev&reg; for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3145-3152.	4.3	5
67	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 727-733.	1.5	5
68	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2816-2825.	2.3	5
69	Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely. <i>Journal of Viral Hepatitis</i> , 2020, 27, 951-954.	2.0	5
70	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. <i>PLoS ONE</i> , 2015, 10, e0144777.	2.5	5
71	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 1082-1087.	1.7	5
72	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. <i>Journal of Korean Medical Science</i> , 2014, 29, 1113.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 393.	8.9	4
74	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	1.5	3
75	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.9	2
76	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.1	2
77	The First Case of <i>Clostridium saudiense</i> Bacteremia in a Patient with Hepatocellular Carcinoma. <i>Annals of Laboratory Medicine</i> , 2022, 42, 491-493.	2.5	2
78	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	2.3	1
79	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 194-204.	1.7	1
80	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.6	0
81	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	1.5	0
82	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq0 0 0 rgBT /25erlock 10 Tf 50 37		
83	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-8.	1.5	0